Market Overview

US Bioservices Selected by Alnylam Pharmaceuticals as a Specialty Pharmacy Partner for ONPATTRO™ (patisiran)


Specialty pharmacy to support bringing new FDA-approved medicine to

US Bioservices, a specialty pharmacy that is a part of
AmerisourceBergen, announced today that it has been selected by Alnylam
Pharmaceuticals to be one of the specialty pharmacies to dispense
ONPATTRO™ (patisiran) lipid complex injection. ONPATTRO was approved by
the U.S. Food and Drug Administration on August 10, 2018 for the
treatment of the polyneuropathy of hereditary transthyretin-mediated
amyloidosis (hATTR) in adults and is a RNA interference (RNAi) therapy
targeting transthyretin (TTR). Prior to the approval of ONPATTRO, there
were no FDA-approved treatment options for hATTR amyloidosis. US
Bioservices will provide comprehensive specialty pharmacy services to
patients who are being treated with ONPATTRO.

"US Bioservices is proud to partner with Alnylam to facilitate access to
treatment and provide integrated, personalized solutions to patients
with this devastating disease," said Kelly Ratliff, President of US
Bioservices. "Over the past two decades, we have innovated to keep pace
with the rapidly changing medical and scientific landscape, and we
welcome the opportunity to support hATTR amyloidosis patients with
polyneuropathy who are prescribed ONPATTRO."

ONPATTRO is administered via intravenous infusion by a healthcare
professional once every three weeks, and will be available through the
specialty pharmacy channel at both infusion clinics and in the patient's
home, if covered under the patient's insurance plan. US Bioservices has
offered home infusion services since its inception over 20 years ago –
providing the option for infusion and nursing services in the
convenience of the patient's home. Because the company has a unique
understanding of, and appreciation for, the complexities associated with
intravenous infusions, especially for rare diseases, US Bioservices can
provide specialized and caring patient support.

Patients prescribed ONPATTRO who receive services from US Bioservices
will have access to its national team of in-home nurses who deliver
trusted care and infusions in the convenience of a patient's home. The
company's telephonic nurses will be available to provide 24/7 clinical
support to patients on therapy. In-home and telephonic nurses work in a
clinically-coordinated way with the prescribing physician and other
members of the patient's care team to improve access, adherence and

ONPATTRO is distributed through a limited distribution network. To get
started with ONPATTRO, healthcare professionals can visit
to access the Alnylam Assist Start Form. Alnylam Assist Case Managers
will reach out within 1-2 business days of receipt of a completed Start
Form and will coordinate with US Bioservices to arrange dispensing and


Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated
with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated
patients experienced IRRs, compared to 9% of placebo-treated patients.
The most common symptoms of IRRs with ONPATTRO were flushing, back pain,
nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a
corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers)
at least 60 minutes prior to ONPATTRO infusion. Monitor patients during
the infusion for signs and symptoms of IRRs. If an IRR occurs, consider
slowing or interrupting the infusion and instituting medical management
as clinically indicated. If the infusion is interrupted, consider
resuming at a slower infusion rate only if symptoms have resolved. In
the case of a serious or life-threatening IRR, the infusion should be
discontinued and not resumed.

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels.
Supplementation at the recommended daily allowance (RDA) of vitamin A is
advised for patients taking ONPATTRO. Higher doses than the RDA should
not be given to try to achieve normal serum vitamin A levels during
treatment with ONPATTRO, as serum levels do not reflect the total
vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular
symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with
ONPATTRO were upper respiratory tract infections (29%) and infusion
related reactions (19%).For additional information about ONPATTRO, see
the full Prescribing Information at

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at

View Comments and Join the Discussion!